CROI 2015 Program and Abstracts

Keyword Index

• Incidence; 22LB, 626, 625, 624, 625, 626, 991LB, 1046, 1042, 1047, 1117 • Infected children and adolescents; 78 • Infected patients; 381 • Infection; 139, 197, 210, 640, 750, 767, 784, 788, 824, 844, 957, 1033, 1039 • Interventions; 176 • Latency; 61, 388, 407, 408, 409, 424 • Malignancies; 71 • Mortality; 1076 • Pathogenesis; 302 • Persistence; 108, 109, 267, 386, 396 • Positive children; 915, 929 • Positive unaware; 1070 • Prevention; 6, 20, 25, 241, 252, 895, 970, 972, 975, 981, 982, 1039 • Production; 549 • Provirus; 379 • Recent (early) infection; 244 • Replication control; 52, 328 • Reservoir; 106, 168, 373, 376, 378, 382, 383, 386, 390, 399, 429, 430, 535 • Restriction and host factors; 189 • Risk; 1028, 1062 • RNA; 568 • RNA suppression; 920 • Self-testing; 1098 • Serodiscordant couples; 988, 989, 1019LB • Shedding; 30 • Status; 715, 1037 • Subtype; 594, 1044 • Surveillance; 99, 1092 • Surveillance data; 665, 854 • Susceptibility; 860 • Testing; 98, 177, 614, 1013, 1018, 1071, 1073, 1099, 1100, 1101 • Transmission; 54LB, 211, 218, 252, 289, 404, 1020, 1095, 1121 • Transmission clusters; 241, 242

• Persistence; 380, 420 • Protease; 586 • Reactivation; 398 • Reservoir; 35, 380, 398, 417, 422 • RNA; 48 • Single-copy assay; 912 • Specific T cells; 377 • Subtype C; 54LB

Human rhinovirus; 356 Humanized mice; 368, 543, 677 Humans; 279 Humoral immunity; 430, 834 Humoral response; 237 HVTN505; 55LB Hydroxymethylglutaryl-CoA reductase inhibitors; 750

Hypercholesterolemia; 733 Hyperparathyroidism; 791 Hypertension; 739, 740 – I – ICAM-1; 735 IDU; 1028, 1121 IFITM; 189 IFITM3; 190 IFN; 185 IFN-a; 285 IFN-alpha; 367 IFN-g; 678 IFN-g secretion; 679 IFNOE±; 283 IL-18; 313 IL-23; 329 IL-27; 301, 301 IL-32; 296 IL-7; 337 IL1-alpha; 464 Illegitimate integrations; 381 Illumina MiSeq; 261, 592 Imaging; 756, 1089 Immigrant; 1078 Immune; 321 IgG; 709 IL-1; 311 IL-6; 752 IL-10; 311 IL-12/IL-15; 678

• Subtypes; 234 • Subtyping; 258

• Transmission; 251 • Unspliced RNA; 384 • Vaccine; 348, 356 • Viral load; 866 • Vpu; 536 HIV-2; 222, 541, 576, 588, 614, 621 HIV-associated neurocognitive disorders (HAND); 437, 441, 450, 461, 464, 465, 466, 480, 492 HIV-exposed; 883 HIV-exposed children; 885 HIV-exposed infants; 884 HIV-exposed uninfected; 289, 877 HIV-infected; 780 HIV-infected adults; 155, 570, 747 HIV-infected children; 35, 36, 513, 920, 939, 956 HIV-infected infants; 884 HIV-infected men who have sex with men; 672, 674 HIV-infected population; 845

HIV-M; 232 HIV-O; 232 HIV-specific CD8T cells; 53, 369 HIV/AIDS; 458, 558, 843 HIV/CMV coinfection; 303 HIV/HBV coinfection; 703, 704, 705

HIV/HCV Coinfection; 152LB, 598, 637, 645, 649, 651, 654, 655, 659, 677, 678, 680, 683, 689, 692, 695, 698, 942

HIV/TB Coinfection; 93, 820, 830 HIV+NSG-HuPBMC mice; 508 HLA; 275, 276, 293, 362 HLA alleles; 328, 924 HLA class I; 228 HLA-associated polymorphisms; 328 HLA-G; 360 HMGB1; 285, 722 Home HIV testing; 1102 Home HIV testing and counseling; 1090, 1111

• Activation; 59, 168, 183, 188, 268, 281, 305, 311, 313, 314, 318, 320, 322, 330, 333, 415, 683, 684, 752, 756, 797, 849, 900 • Checkpoint; 388 • Exhaustion; 330, 849 • Recovery; 914 • Reconstitution; 335, 818 • Recovery; 548, 1015 • Response; 393, 466, 815, 986 • Restoration; 575 • Senescence; 305, 923 Immune reconstitution inflammatory syndrome (IRIS); 308, 309, 310, 311, 810, 811, 812, 813, 814, 815, 836 Immunodiscordant individuals; 331 Immunogenicity; 348 Immunohistochemistry; 298LB Immunologic • Biomarker; 317 • Failure; 570 • Progression; 333 • Response; 315, 572, 576 Immunology; 273 Immunomodulation; 87, 405, 821

• Transmission Linkage; 240, 244, 1035 • Treatment as prevention; 127, 1019LB • Treatment cascade; 154, 852 • Tropism; 221, 431 • Vaccine; 166 • Viral evolution; 492 • Viral load; 865, 582, 865, 924, 997, 1112

HIV-1; 28, 35, 40, 43, 45, 46LB, 117, 118, 165, 183, 185, 189, 195, 196, 214, 220, 230, 235, 247, 261, 262, 352, 399, 404, 423, 434, 470, 539, 543, 550, 554LB, 574, 585, 600, 614, 615, 621, 633, 834, 870, 898, 916, 919, 933, 950, 988, 1084, 1089 • Cell-associated RNA; 912 • Diversity; 231

Home testing; 1097 Homocysteine; 470 Honduras; 607 Hormonal contraception; 858 Hospitalizations; 783, 877 Host factors; 195, 197 Host genetics; 291, 294, 460, 515 Host restriction factors; 386 Host-pathogen interaction; 123 Host-virus interactions; 41 Hotspots; 199 Household contacts; 817 HPV; 90, 568, 710, 716, 856 HSCs; 207 HSIL; 90

• DNA; 377 • Env; 327 • Eradication; 391 • Evolution; 41 • Gag epitopes; 365 • gp120; 327

Keyword Index

• Infection inhibition; 213 • Infection phenotypes; 261 • Inhibition; 967 • Integrase; 121, 610 • Integration; 198 • Latency; 368, 369, 393, 415, 417, 419 • M/O recombinant; 233

HSV-2; 28, 855, 1084 HSV-2 inhibition; 967 HTLV-1; 214 Human herpesvirus 8; 87

Immunoprophylaxis; 66 Immunosenescence; 820 Immunotherapy; 50, 337 Impact evaluation; 158 Implementation science; 7, 20, 721, 1113 In vitro; 211, 519, 785 In vivo; 425

Human ICAM-1 transgenic mice; 356 Human immunodeficiency virus; 410 Human papillomavirus; 713, 943

• Mouse model; 528 • Neutralization; 589

686

CROI 2015